What Keeps Patients in Medical Cannabis? Burden, Not Medicine

Photo by https://kaboompics.com/ via Pexels.

Two numbers from two continents, published the same week. German medical cannabis patients rated buying on the illegal market an 8.1 out of 10 for stress, against 1.8 for picking up a prescription at a pharmacy. In Massachusetts, year-to-date medical sales to patients and caregivers fell from $17.9 million in September 2023 to $11.2 million last month.

Coverage treats these as separate stories, one about pharmacies being better and one about a program in decline. I think they are the same story. Both numbers measure what the legal alternative costs, in stress, money and paperwork, and say much less about how good the medicine is. A medical program holds patients when the other door is risky or burdensome, and loses them when the other door is a licensed shop on the corner.

A caution before I lean on the German figure: it comes from a company press release, and I could not trace it to a questionnaire. The argument still holds if you discount the survey heavily, because the Massachusetts half stands on regulator data and the German half needs only the plain fact that illicit buying carries risk. Here is how I get there, and where it could break.

The German Number, and Who Is Selling It

The German finding was published in a press release dated Frankfurt, Oct. 22, 2026, from Bloomwell Group GmbH, and carried by Cannabis Business Times under a press-release label. It is not independent research. Bloomwell sells telemedicine-based medical cannabis care, and its CEO, Dr. med. Julian Wichmann, is quoted saying the illegal market makes people sick. That is a company with a stake in how pharmacy access is perceived.

The sample is 7,913 medical cannabis patients. Of those, 7,062 had used both pharmacies and the illegal market, and the preference figures come from that subgroup. Big numbers, but a sample size is not a sampling method.

I could not find the questionnaire, the recruitment method or the fieldwork dates. Recruitment probably ran through Bloomwell's own platform, but I could not confirm it, and anyone building on this survey should ask the company directly.

Selection bias is likely, and that is my inference, not a sourced claim. Respondents are people already inside a legal channel, often customers of the sponsor. Marijuana Herald says the results reflect reported perceptions and should not be treated as representative of all German patients. I agree with that reading, and I will use the survey as a signal about direction, not as a measurement of the whole market.

What the Survey Actually Measures: Stress and Price

Buyers rated illegal cannabis purchases far more stressful than pharmacy purchases, at 8.1 versus 1.8 on a 10-point scale. Source: Cannabis Business Times.

Strip the framing and the headline is a rating gap. On a 1 to 10 scale, with 10 the most stress, respondents averaged 8.1 for illegal purchasing and 1.8 for pharmacies. Bloomwell calls that 4.5 times as stressful. The other figures, all from the subgroup who had used both channels, follow the same pattern:

• 96.7% called pharmacy cannabis cleaner and purer.
• 98.2% said they feel better informed and advised at pharmacies.
• 94.4% said pharmacy cannabis is cheaper.

The price claim has a number behind it: an average flower price of €3.77 per gram, with options starting under €2. That makes the legal route cheap as well as calm. Stated reasons for choosing pharmacies were general well-being at 79.8%, contaminant concerns at 77.8% and product transparency at 77.4%.

Notice what kind of answers these are. Cleaner, better informed, cheaper, less stressful: each describes the experience of getting the product, and the purity and transparency items are perceptions, not lab comparisons. Nobody ran these samples through a chromatograph.

My read is narrow. The survey shows the illegal alternative is costly in stress, money and uncertainty for these respondents. It says nothing about whether pharmacy cannabis is better medicine, and that is the claim the headline invites. A patient can be loyal to a pharmacy purely because the other option is worse.

Massachusetts: When the Card Stops Paying for Itself

Now the second half. Cannabis Control Commission data show year-to-date medical sales to patients and caregivers falling from $17.9 million in September 2023 to $11.2 million last month. By my arithmetic that is roughly a 37% drop; the source does not state a percentage.

The sources I read attribute the decline to nothing specific. Adult-use substitution is my thesis, not a documented cause, and I want that line kept clear. What I can lay out is the logic. Where a retail shop will sell to any adult 21 and over, a medical card adds cost and paperwork and removes little friction. For a casual or moderate user, the card has stopped paying for itself.

The data have limits. The CCC holds medical sales data only from after December 2018, when the program moved from the Department of Public Health to Metrc. That makes long trend comparisons thin, and it means I cannot say what the curve looked like before adult-use shops matured.

Two things would test the idea. One is the CCC's patient-count trend, which I did not retrieve. Falling sales with a steady patient count would point to patients buying less through the card, while a falling count points to people leaving it. The other is who remains. If the patients still buying are heavy or high-need users, the card is holding those with the most to gain from whatever it offers, and the rest have rationally walked away.

A Working Model: What Makes a Program Shrink or Hold

Here is the working model. Retention in a medical program is roughly the gap between the burden of the alternative and the burden of the medical channel. When the alternative is costlier, patients stay. When the gap closes or reverses, they leave.

Apply it to Germany. The alternative is the illegal market, high in stress and uncertainty. The medical channel is, by respondents' account, low in stress and cheap. The gap is wide, so patients stay.

Apply it to Massachusetts. The alternative is a licensed retail store with low risk and low burden. The medical channel asks for a certification and delivers little extra. The gap is small or negative, and the program shrinks.

The cases are not symmetrical. Germany's survey compares legal with illegal channels, while Massachusetts compares two legal ones. The shared thread is the relative cost of access, which is why I trust the model more than either case alone.

For any program, these are the signs I would check:

1. How easy adult-use retail is: distance, hours, age rules, whether shops exist at all.
2. Price or tax advantages for patients over adult-use buyers.
3. Insurance coverage, which can erase the price gap.
4. What the card offers beyond access, such as higher potency limits or tax relief.
5. How risky or stressful the unlicensed option remains where the patient lives.

A program scoring low on the first four is a candidate for shrinkage once adult-use arrives. One scoring high on the fifth will look healthy for reasons that have little to do with its medicine.

The Strongest Objection, and Germany's Fragile Side

The strongest objection is that patients stay because pharmacy product and clinical guidance are simply better. The survey's 98.2% who feel better informed points that way. But that figure is self-reported and sponsor-collected, from people who bought a telemedicine service.

My reply is that the stress and price ratings measure burden, and the quality claims are perceptions, not lab results. The thesis does not need quality to be false. It needs only to show that quality is unnecessary to explain retention. If the illegal option scores 8.1 for stress, patients have a reason to stay even with mediocre pharmacy product.

The press release offers a sharper clue. It cites a summer 2025 survey in which 41% said they would return to the illegal market if telemedicine were restricted. People who say that are telling you access, not the medicine, is what holds them.

That makes Germany's position fragile, and two claims in the release matter. It says health insurers have no longer covered patients' costs since the end of July 2026. It also says the Federal Ministry of Health is pushing a draft MedCanG amendment that, per StratCann, would heavily restrict telemedicine and mail-order shipping. Both are company claims I could not verify, and I could not check the amendment's current status. Check official German sources before relying on either.

Our earlier piece, Germany's Cannabis Clubs, One Year On, shows the other legal alternatives are still being built. That helps explain why the pharmacy comparison is so lopsided: the pharmacy is competing against the illegal market, not against a mature legal retail rival. As those options develop, the gap the model depends on may narrow.

Question 8 Would Flip the Massachusetts Dynamic

Which brings me to Massachusetts, where a test is coming. Question 8 asks voters next month to repeal the recreational market, and Massachusetts would be the first state to dismantle one. Retail stores would have to become medical dispensaries or sell their inventory to one, and the CCC would keep regulating medical sales.

By the model, this flips the dynamic. Remove easy adult-use access and the card becomes the only legal route. The medical channel's relative burden falls, because the alternative is now the unlicensed market, which is where Germany's patients say the stress lives.

The CCC is already moving on access. Its Oct. 22 proposal would drop the residency requirement for adults 18 and over from any state who have a debilitating medical condition certified by a Massachusetts provider. Minors would need a life-limiting illness certified by two providers. Commissioner Xiomara DeLobato said it would give medical patients across the country more access.

Massachusetts and Vermont are the only New England states that bar non-residents from medical marijuana. Ryan Dominguez, executive director of the Massachusetts Cannabis Coalition, tied the proposal to Question 8. The Oct. 22 discussion was mainly about widening access, with the sales decline as context, not a standalone debate on the decline.

The schedule: an initial vote on Dec. 10, public comment from Jan. 1 to Feb. 2, then a final vote. Question 8's result falls after my reporting date, so what follows is a prediction, not an outcome. If the measure passes, I expect medical demand to recover. If it fails, I expect the slump to continue.

Retention numbers are best read as a price on the alternative. A program that looks healthy may just be sheltering patients from something worse, and a program that looks like it is dying may only have been outcompeted by an easier legal door. Neither says much about the medicine inside.

The test is concrete. If Question 8 passes and Massachusetts medical sales rebound, the burden model gains support. If they stay flat, I have to revise it, perhaps toward the idea that patients leaving for adult-use do not come back, or that sales hinge on factors I have not measured. I would rather be wrong in public than right by vagueness.

Browse our seed collection.